Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 9;25(18):4112. doi: 10.3390/molecules25184112

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The effect of EP on oxidative phosphorylation (OXPHOS) and ROS production in differentiating Treg. (A) Relative protein expression of mitochondrial transport chain complexes 72 h after EP administration. The impact of rotenone (simultaneously applied with EP) on (B) EP-driven Treg (CD4⁺CD25^highFoxP3⁺) proportion or (C) ROS formation, measured by dihydrorhodamine 123 (DHR) staining. (D) Timeline of ROS production per Treg (CD4⁺CD25^high) and (E) the proportion of ROS-producing Treg in control and EP-treated cells. Representative dot plots are shown below the graph. * p < 0.05 represents the significant difference of EP- or rotenone-treated cells in comparison to untreated control cells, while # p < 0.05 represents the significant difference between rotenone+EP-treated cells in comparison to EP-treated cells.